New routine vaccines to boost adult and adolescent segment
Posted Sep 09 2010 4:21am
Vaccines to 2014
US demand to grow 5.5% annually through 2014 Demand for vaccines is forecast to increase 5.5 percent annually to more than $14 billion in 2014. The market has experienced dramatic growth due to increasing routine seasonal influenza immunization and the rising number of preventive and booster vaccines available for adults and adolescents. This growth will be compounded as several new therapeutic vaccines for cancer reach the market, followed in the coming years by biological treatments for Respiratory Syncytial Virus (RSV) and Alzheimer’s Disease, and a variety of new vaccines for travel and biodefense. ( http://www.bharatbook.com/detail.asp?id=149759&rt=Vaccines-to-2014.html )
New routine vaccines to boost adult, adolescent segment Pediatric vaccines have been the mainstay of the vaccine market for many years, growing steadily as new products emerged and as a greater number of routine vaccinations were encouraged. Now, a substantial number of primary vaccines and boosters are being recommended for adolescents and older adults, and the market for vaccines has expanded dramatically with the addition of these populations to the target markets for vaccine producers. Significant growth in the market has been fueled by the introduction of a vaccine for Human Papillomavirus (HPV), recommended for girls and young women and now being considered for males and a wider age range. Seasonal influenza vaccination is also gaining ground and represents a substantial portion of growth in adult vaccines, as new preventive treatments against zoster and meningococcal disease. Also a factor in adult vaccines is the growing use of boosters against tetanus, diphtheria, pertussis and other diseases.
Combination vaccines to pace pediatric products Among vaccines for children, sales will be affected by the expiration of patent protection for many of the most widely used vaccines. This has encouraged producers to develop several new combination vaccines, which will serve to maintain the value of products while decreasing the burden of multiple individual injections. Traditional DTaP (diphtheria, tetanus, pertussis) vaccines are being supplemented by products for Hepatitis B and polio or Haemophilus b.Also being developed are vaccines to address a wider range of bacterial serotypes, as with Wyeth’s blockbuster PREVNAR7, which has been expanded to address 13 serotypes and which is recommended as a supplement for children who already received the earlier vaccine. Relatively new vaccines, such as that for Rotavirus, continue to mature and to reach greater immunization coverage.
Many new therapeutic vaccines showing promise Vaccine demand will be spurred considerably by a number of therapeutic vaccines for cancer that are nearing completion of clinical trials and are poised for FDA approval. There are currently 50 cancer vaccines in phase III or later trials, and the activity surrounding cancer vaccine development is expected to continue at a high pace. Also showing promise are vaccines being developed for RSV, HIV and Alzheimer’s Disease. Similarly, a range of vaccines for travel, developing countries and biodefense are in the pipeline, including prophylactics for malaria, hemorrhagic fevers, West Nile virus and plague.